



Progression Analysis with ABCD Grading System Following Corneal Collagen Cross-Linking in Keratoconus

Ayhan Saglik,¹ Mehmed Ugur Isik²

¹Department of Ophthalmology, Harran University, Şanlıurfa, Turkey

²Department of Ophthalmology, Balıklıgöl State Hospital, Şanlıurfa, Turkey

Abstract

Objectives: To evaluate the ABCD grading system used in follow-up of keratoconus progression after the corneal collagen cross-linking (CXL) treatment in different Kmax groups.

Methods: This study included 57 eyes of 43 patients applied with CXL treatment for progressive keratoconus. All the patients were applied with the standard CXL protocol (Dresden). According to the changes in the Kmax value at the end of 12 months postoperatively (0–1D, 1–2D, >2D), the groups were separated as steepening and flattening. Scheimpflug progression parameters, such as ABCD keratoconus grading systems were evaluated in six different groups. The Paired Samples t-test was used in the evaluation of parameters with normal distribution and the Wilcoxon test for parameters not showing normal distribution. A value of $p < 0.05$ was accepted as statistically significant.

Results: Mean age of patients was 18.37 ± 3.86 years (11–28 years). According to the ABCD grading system, 0.19 significant regression was determined in grade A ($p = 0.014$), and 0.24 in grade D ($p < 0.0001$). 0.10 progression was seen in grade B ($p = 0.089$), and 0.11 in grade C ($p = 0.011$). In the mean Kmax value 0.25 ± 0.42 D flattening was seen ($p = 0.137$).

Conclusion: The anterior corneal surface grade in ABCD system is correlated with Kmax in different groups. But the posterior corneal surface parameter is not correlated with Kmax in 1–2 D steepening and >2D flattening groups. Although there is an increase in posterior elevation after CXL, despite excessive Kmax flattening, it would be inaccurate to consider this increase as an indicator of topographic progress.

Keywords: ABCD grading system, cross-linking, keratoconus, maximum keratometry, progression analysis.

Introduction

Keratoconus is a corneal ectasia that can lead to irregular astigmatism, progressive corneal thinning and corneal scarring. It generally starts in puberty and progression can show variability from patient to patient (1, 2).

Riboflavin and ultraviolet-A-induced corneal collagen cross-linking (CXL) treatment is a surgical procedure that has been applied for more than 10 years to slow the progression of keratoconus. Cross-linkages photochemically

activated within the stromal collagen network increase the biochemical stability of the cornea (3–5). The clinical and topographic findings of several studies have shown that CXL treatment slows the progression of keratoconus (6–8).

There are currently several corneal analysis methods, such as keratometry, pachymetry, topography and tomography which have an important place in the diagnosis of keratoconus and in follow-up after CXL treatment (9). In addition, a clearer and more sensitive analysis can be obtained

Address for correspondence: Ayhan Saglik, MD. Harran Universitesi, Oftalmoloji Anabilim Dalı, Sanliurfa, Turkey

Phone: +90 536 356 11 71 **E-mail:** saglikayhan@yahoo.com

Submitted Date: May 05, 2019 **Accepted Date:** October 10, 2019 **Available Online Date:** October 14, 2019

©Copyright 2019 by Beyoglu Eye Training and Research Hospital - Available online at www.beyoglueye.com

OPEN ACCESS This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



of ectatic changes in the cornea using anterior and posterior elevation data and pachymetric data of the Belin-Ambrosio Enhanced Ectasia Display (BAD) (available on the Pentacam, OCULUS GmbH, Wetzlar, Germany) (10, 11).

The aim of this study was to evaluate the ABCD grading system used in follow-up of keratoconus progression after the corneal cross-linking treatment in different Kmax groups. The findings of the study can be considered as important guidance in respect of the comparison of topographic parameters commonly used in the follow-up of the progression of keratoconus.

Methods

Study Population

This retrospective study included 57 eyes of 43 patients applied with CXL treatment for progressive keratoconus in the Ophthalmology Department between December 2016 and October 2018. Approval for the study was granted by the Local Ethics Committee and all procedures were conducted in accordance with the Helsinki Declaration (Ethics acceptance no: 18/ 05/ 21). Written informed consent for publication of this clinical details and/or clinical images was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.

The diagnosis of keratoconus was made from tomography findings such as asymmetric bow-tie pattern and inferior-superior (I-S) asymmetry obtained with Scheimpflug imaging (Pentacam HR; Oculus GmbH, Wetzlar, Germany).

Inclusion and Exclusion Criteria

Only patients with progressive keratoconus were included in this study. An increase of >1D in the Kmax value between 2 consecutive examinations (at least 6 months of follow-up) before corneal CXL treatment was accepted as progression criteria.

Patients were excluded from the study if the thinnest corneal thickness (pachymin) obtained on Scheimpflug imaging was <400µm, if they had excessive axial corneal scarring, ocular trauma, a history of ocular surgery, herpetic keratitis, any autoimmune disease, were pregnant, or had used contact lenses within the previous month.

Preoperative and Postoperative Measurements

Measurements of all the eyes included in the study were taken with a Pentacam HR (OCULUS GmbH, Wetzlar, Germany). Patients had stopped wearing contact lenses at least 1 month before the measurements. The Scheimpflug images were obtained by a single researcher experienced in this procedure in the Cornea Unit of Ophthalmology Department. If the image quality was not automatically checked and labelled as "OK", the evaluation was repeated. Only the images which passed the quality control as "OK" were included in the study. This approach provided greater reliability of the

measurements. At least two measurements were taken from all patients to assess repeatability. The variables used for follow-up of progression after CXL treatment were measured before CXL and at 12 months after CXL. The differences between the measurements were analysed.

According to the changes in the Kmax value at the end of 12 months postoperatively (0-1D, 1-2D, and >2D), the groups were separated as steepening and flattening. In the follow-up of progression, the ABCD keratoconus grading system was used, which was scored from 0 to 4 by the Pentacam (10). The letters used in this grading system correspond to the following: "A" calculated from ARC (corneal curvature at 3mm from the thinnest point on the anterior corneal surface), "B" calculated from PRC (corneal curvature at 3mm from the thinnest point on the posterior corneal surface), "C" calculated from pachymin (thinnest pachymetry), and "D" (Distance best corrected vision) (Table 1). After the CXL treatment, increases in these parameters were considered as progression while decreases were considered as regression.

The parameters were examined of Kmax, minimum pachymetry (Pachymin), front elevation in thinnest location (F.ele.th.), back elevation in thinnest location (B.ele.th.) and the Ambrósio relational thickness maximum (ARTmax) value, calculated using the formula below (12):

$$ART_{max} = \frac{Tp}{PPI_{max}}$$

Tp: Thinnest pachymetry

PPI_{max}: Pachymetric progression index maximum

Surgical Technique

All the patients were applied with the standard CXL procedure as defined by Wollensack et al. (13) Anaesthesia was provided before the procedure with proparacaine hydrochloride 0.5%, then 0.9 mm corneal epithelium was separated using a crescent knife. After corneal thickness measurement with ultrasonic pachymetry (UP), isotonic riboflavin (0.1% Riboflavin with 20% Dextran T500) (Collagex, Taipei, Taiwan) was dropped at 2-min intervals for 30 mins. Riboflavin absorption in the anterior chamber was checked with a slit-lamp biomicroscope, then measurements were taken again with UP.

Before the UVA process, if the corneal thickness thinner from 400 µm, a hypotonic riboflavin solution (0.1% in sterile water) (Collagex, Taipei, Taiwan) was applied as 1 drop every 10 seconds for 2 mins.

When the corneal stromal thickness was seen to be ≥400µm with UP, UVA light of 365nm (LightLink-CXL, LIGHTMED, Taiwan) was applied at irradiance of 3.0mW/cm² for 30 mins. In cases where hypotonic riboflavin was required, a hypotonic riboflavin solution was continued every

Table 1. Proposed ABCD keratoconus grading system (10)

ABCD criteria	A ARC (3 mm zone)	B PRC (3 mm zone)	C Thinnest pach (μm)	D BDVA
Stage 0	7.25mm (<46.5 D)	$>5.90\text{mm}$	$>490 \mu\text{m}$	$\geq 20/20$ (≥ 1.0)
Stage I	7.05mm (<48.0 D)	$>5.70\text{mm}$	$>450 \mu\text{m}$	$<20/20$ (<1.0)
Stage II	$>6.35\text{mm}$ (<53.0 D)	$>5.15\text{mm}$	$>400 \mu\text{m}$	$<20/40$ (<0.5)
Stage III	$>6.15\text{mm}$ (<55.0 D)	$>4.95\text{mm}$	$>300 \mu\text{m}$	$<20/100$ (<0.2)
Stage IV	6.15mm (>55.0 D)	$<4.95\text{mm}$	$\leq 300 \mu\text{m}$	$<20/400$ (<0.05)

Stages (0 to IV) are based on anterior and posterior radius of curvature (ARC, PRC), thinnest pachymetry, best corrected distance visual acuity (BDVA). ARC: corneal curvature at 3 mm from the thinnest point on the anterior corneal surface, PRC: corneal curvature at 3 mm from the thinnest point on the posterior corneal surface, thinnest pach: thinnest pachymetry.

2 mins during the application of UVA.

Postoperatively, a soft contact lens was applied and topical antibiotic drops were used 4 times a day. Following epithelial healing, the lens was removed and topical steroid treatment was started at the dose of 4 times a day for 2 weeks and this was continued for up to 3 months with a gradually tapering dose.

Statistical Analysis

The comparisons of the first and second measurements were statistically analysed using SPSS vn 24 (IBM). For evaluation of repeatability, the intraclass correlation coefficient (ICC) and its 95% confident interval (CI) were determined. An ICC greater than 0.7 is considered acceptable, greater than 0.8 is considered good, and greater than 0.9 is considered excellent (14). Furthermore heat map analysis was performed to examine the distribution of the data in all patients. Conformity of the data to normal distribution was assessed with the Shapiro-Wilk test. Descriptive statistics (mean \pm standard deviation) were used in the evaluation of data with normal distribution, and data not showing normal distribution were stated as median and interquartile range (IQR) values. The Paired Samples t-test was used in the evaluation of parameters with normal distribution and the Wilcoxon test for parameters not showing normal distribution. A value of $p < 0.05$ was accepted as statistically significant.

Results

The patients comprised 23 females and 20 males with a mean age of 18.37 ± 3.86 years (11–28 years); 19 (44%) patients

were aged <18 years and 24 (56%) were >18 years. The eyes treated in the study were 30 (53%) right-side, and 27 (47%) left-side. The application of hypotonic riboflavin solution was necessary in 6 (10%) eyes.

The topographic parameters before CXL and at 12 months postoperatively of all the patients are shown in Table 2. The ICC and its 95% CI were found greater than 0.9 in repeatability analysis of different Kmax measurements. In the mean Kmax value 0.25 ± 0.42 D flattening was seen ($p = 0.137$). A statistically significant reduction was determined in the A grade, D grade, pachymin, F.ele.th, and ART-max values ($p = 0.014$, $p < 0.0001$, $p = 0.005$, $p = 0.008$, $p = 0.024$ respectively). A statistically significant increase was determined in the ARC and C grade ($p = 0.007$, $p = 0.004$ respectively). According to the ABCD grading system, statistically significant regression was determined in grade A ($p = 0.014$) and grade D ($p < 0.0001$). Significant progression was seen in grade C ($p = 0.004$) (Table 2).

The topographic progression parameters evaluated according to the change in the Kmax value and the 12-month follow-up period are shown in Table 3 and Table 4. In the Kmax values, 0–1D flattening was determined in 21 (37%) eyes, 1–2D flattening in 9 (16%) eyes, and ≥ 2 D flattening in 4 (7%) eyes. Steepening of 0–1D was determined in the Kmax values of 13 (23%) eyes, 1–2D in 9 (16%) eyes, and ≥ 2 D in 1 (1%) eye. Particularly in >2 D flattening group, abnormal measurements between ABCD grading system were observed. While there was 0.95 regression in the grade A and 0.32 regression in the grade D, 0.43 progression was determined in grade B and 0.42

Table 2. Mean values and differences of topographic indices before and after CXL treatment

	Pre-CXL	Post-CXL month 12	Mean Difference	p
Kmax (D)	55.88±5.23	55.63±5.29	-0.25±0.42	=0.137
Pachymin (µm)	447.30±35.84	440.81±37.37	-6.66±17.16	=0.005*
ARC (mm)	6.60±0.44	6.70±0.49	0.08±0.23	=0.007*
PRC (mm)	5.00±0.43	4.99±0.45	-0.01±0.10	=0.152
A	2.83±1.31	2.60±1.36	-0.19±0.56	=0.014*
B	4.04±1.80	4.13±1.86	0.10±0.47	=0.102
C	1.98±0.72	2.12±0.73	0.13±0.34	=0.004*
D	2.57±0.80	2.32±0.75	-0.24±0.42	<0.0001*
ARTmax	166.61±44.17	158.59±46.95	-8.01±26.04	=0.024*
Fele.Th. (µm)	21.83±8.38	18.87±9.06	-2.04±5.66	=0.008*
B.ele.Th. (µm)	44.83±16.76	45.00±17.25	0.21±5.38	=0.769

*statistically significant (p<0.05); Kmax: maximum keratometry, ARC: corneal curvature at 3mm from the thinnest point on the anterior corneal surface, PRC: corneal curvature at 3mm from the thinnest point on the posterior corneal surface, pachymin: thinnest pachymetry, Fele.th: front elevation in thinnest location, B.ele.th: back elevation in thinnest location, ARTmax: Ambrósio relational thickness maximum.

progression in grade C (Fig. 1), (Table 4).

Considering the difference between the initial and final values, there was no significant relationship between the change in Kmax values and the change in the stages of B and C grades. However, there was a significant correlation between the change in Kmax values and the change of A

Table 3. Mean differences of topographic indices after CXL treatment in Kmax steepening groups

	Kmax 0-1D † (n=13)	Kmax 1-2D † (n=9)
Age	18.58±4.67	18.20±1.32
M-Kmax (D)	56.63±5.11	55.13±3.70
(Range)	(49.20-66.80)	(49.40-61.10)
Kmax (D)	0.38±0.25	1.33±0.31
Pachymin (µm)	-0.15±11.43	-10.50±14.78
ARC (mm)	-0.02±0.09	0.03±0.21
PRC (mm)	-0.02±0.08	0.006±0.12
A	0.03±0.40	0.14±0.55
B	0.15±0.38	-0.01±0.58
C	0.01±0.15	0.21±0.30
D	-0.27±0.38	-0.28±0.34
ARTmax	-2.84±15.23	-5.50±22.03
Fele.th. (µm)	-0.05±1.94	-1.70±5.14
B.ele.th. (µm)	1.61±5.66	-2.70±4.80

Kmax: maximum keratometry, Kmax UC: Kmax unchanged group, M-Kmax: mean maximum keratometry, ARC: corneal curvature at 3mm from the thinnest point on the anterior corneal surface, PRC: corneal curvature at 3mm from the thinnest point on the posterior corneal surface, pachymin: thinnest pachymetry, Fele.th: front elevation in thinnest location, B.ele.th: back elevation in thinnest location, ARTmax: Ambrósio relational thickness maximum.

grade (Table 5).

No reduction in CDVA was determined in any eye at the end of 12 months. In 1 patient who developed grade 2-3 haze, and an increase of 2.3D was observed in the Kmax value. The preoperative and postoperative Scheimpflug BAD analyses of this patient are presented in Figure 2.

Discussion

Corneal collagen CXL treatment for keratoconus is known to halt or slow down progression of the disease (15) In this study, the changes in prognostic data obtained from the Scheimpflug system were examined 12 months after CXL treatment for keratoconus. Although several previous studies have made comparisons of standard topographic data pre and post CXL, (6-9) There are still some deficiencies in the use of these parameters when evaluating CXL results (8, 16). Due to abnormal corneal steepening in keratoconus, some standard topographic data are not sufficient in the determination of progression and regression. Therefore, progression indexes such as the BAD display and ABCD grading systems have been developed (10). In the current study, the Kmax value was taken as the pivot and different indexes were compared over the Kmax. The patients were divided into 5 different subgroups according to the steepening and flattening degrees of Kmax values as shown in tables 3 and 4.

In previous studies where conventional CXL treatment has been applied, Wittig-Silva et al. (6) determined (n=100) 1.03 D flattening in the Kmax value in a 3-year follow-up, Hashemi et al. (7) reported (n=40) 0.16 D in a 5-year follow-up, and Chow et al. (17) reported (n=38) 1.6 D in a 1-year follow-up. The Kmax value is frequently used to determine

Table 4. Mean differences of topographic indices after CXL treatment in Kmax flattening groups

	Kmax 0-1D † (n=21)	Kmax 1-2D † (n=9)	Kmax >2D † (n=4)
Age	19.22±3.93	17.44±2.29	17.25±1.25
M-Kmax (D)	55.53±5.13	56.97±6.41	56.62±8.92
(Range)	(48.30-63.90)	(50.20-70.40)	(50.90-70.00)
Kmax (D)	-0.44±0.35	-1.37±0.27	-3.22±1.02
Pachymin (µm)	0.04±11.38	-8.44±7.61	-19.00±17.60
ARC (mm)	0.03±0.05	0.12±0.07	0.27±0.25
PRC (mm)	0.001±0.07	0.001±0.55	-0.10±0.15
A	-0.10±0.19	-0.43±0.32	-0.95±0.74
B	-0.002±0.31	0.004±0.24	0.43±0.75
C	-0.003±0.23	0.16±0.14	0.42±0.43
D	-0.14±0.40	-0.18±0.33	-0.32±0.25
ARTmax	4.76±18.70	-18.11±18.75	-54.00±34.14
F.ele.th. (µm)	-0.85±2.47	-2.66±2.95	-6.00±5.29
B.ele.th. (µm)	-0.09±5.69	-0.11±5.25	2.75±5.90

Kmax: maximum keratometry, Kmax UC: Kmax unchanged group, M-Kmax: mean maximum keratometry, ARC: corneal curvature at 3 mm from the thinnest point on the anterior corneal surface, PRC: corneal curvature at 3 mm from the thinnest point on the posterior corneal surface, pachymin: thinnest pachymetry, F.ele.th: front elevation in thinnest location, B.ele.th: back elevation in thinnest location, ARTmax: Ambrósio relational thickness maximum.

the progression of the disease. Therefore, in order to evaluate the accuracy in predicting progression between the two systems, we investigated the relationship of the difference between the initial and final values in the ABCD grading system and the difference between the initial and final Kmax values. In the current study, (n=57) 0.25 D flattening was determined in the Kmax value as well as a regression in the

A grade with a significant correlation at the end of 1 year (Table 5).

Several studies have reported a thinning of the pachymetry measurements obtained from topography in the early period after CXL treatment, but in the late postoperative period these values have approached the pre-treatment levels (6, 18, 19). Therefore, pachymetric analyses can cause errors in progression analysis after CXL. Similarly, in the current study, progression was determined at 12 months after CXL in the C grade obtained from the pachymin value according to the ABCD grading system. Furthermore, the progression rate in grade C was determined to be greatest in the group with >2D flattening in Kmax (Table 4) (Fig. 1). When we analyze the relationship of the differences at the initial and final values between C grade and Kmax values, the change in C grade in the Kmax <2 D flattening group approached meaningfulness at most but no significant difference was obtained (Table 5). Hence, the greater amount of pachymetric thinning in this group might have developed as a result of excessive corneal thinning rather than the severity of the disease, as previously reported by Kymonis et al. (20).




Figure 1. Evaluation of different Kmax groups according to ABCD grading system.


Kmax: maximum keratometry, A: corneal curvature at 3 mm from the thinnest point on the anterior corneal surface (ARC), B: corneal curvature at 3 mm from the thinnest point on the posterior corneal surface (PRC) and C: thinnest pachymetry (pachymin).

At the end of 12 months, anterior surface assessment of ABCD grading parameters showed a 0.19 decrease in the A grade, 0.10 progression in the B grade in the evaluation of the posterior surface, and 0.24 regression was observed in

Table 5. Correlation between Kmax and A, B, and C grades in differences between baseline and 12th month

Grade	Kmax 0-1D † (n=21)		Kmax 1-2D † (n=9)		Kmax >2D † (n=4)		Kmax 0-1D † (n=13)		Kmax 1-2D † (n=9)		Total (n=57)	
	rho	p	rho	p	rho	p	rho	p	rho	p	rho	p
A	0.279	0.221	0.105	0.788	0.624	0.376	-0.374	0.207	-0.385	0.271	0.482	<0.001
B	-0.051	0.826	0.038	0.922	-0.900	0.100	-0.244	0.422	0.500	0.141	-0.055	0.681
C	-0.377	0.092	0.128	0.743	-0.929	0.071	0.113	0.714	0.564	0.090	-0.119	0.368

Kmax: maximum keratometry.

**Figure 2.** Corneal steepening of >2 D in the Kmax 12 months after CXL treatment in a case.

the D grade (Table 2). Just as in the other results, end-points were determined in the ABCD grading system in the group with >2 D flattening. While there was 0.95 and 0.32 regression in the A and D grades, 0.43 and 0.42 progression was determined in the grade B and C (Table 4). These results showed that excessive anterior surface flattening provided regression at grade A.

At 12 months after CXL, there was seen to be a mean reduction of 2.04 μ m in F.ele.Th and a reduction of 8.01 in ARTmax. These mean data indicated that progression had stopped after CXL in the anterior surface. In the B.ele.Th value, an increase was determined of 1.61 μ m in the Kmax 0-1 D steepening group and 2.75 μ m in the >2 D flattening group (Table 3), (Table 4). There have been reports of increased posterior elevation after CXL (21, 22). It is suggested that posterior steepening together with anterior flattening may be the cause for the stabilization of keratometric values after CXL (22). On the other hand, when we analyzed all eyes, there was an increase in the B.ele.Th value but it was not significant. There were studies also analyzing corneal changes after CXL with Scheimpflug imaging that found no significant changes in the posterior elevation (23, 24). These differences can be explained by ongoing ectatic changes in the posterior cornea or by the insufficiency of existing de-

vices to analyze posterior corneal elevation after CXL.

When we evaluated according to the change in Kmax value at the end of 12 months, the results of the 0-1 D and 1-2 D flattening groups in particular were seen to be more stable and at levels expected after CXL. Flattening of >2 D in Kmax does not seem to be very reliable in respect of topographic parameters. As seen in the current study, despite the excessive corneal flattening, there was a large fall in ARTmax and signs of progression in the posterior surface evaluation.

The low number of subjects and the short follow-up period were the primary limitations of this study. There is a need for further studies with larger samples so that patients can be grouped according to different stages of keratoconus before CXL to be able to compare progression according to ABCD system.

In conclusion, the anterior corneal surface grade in ABCD system seems to be correlated with Kmax in different groups. But the posterior elevation was increased and was not correlated with Kmax in 1-2 D steepening and >2D flattening groups. Although there is an increase in posterior elevation after CXL, despite excessive Kmax flattening, it would be inaccurate to consider this increase as an indicator of topographic progress.

Disclosures

Peer-review: Externally peer-reviewed.

Conflict of Interest: None declared.

References

- Rabinowitz YS. Keratoconus. *Surv Ophthalmol.* 1998; 42:297-319.
- Jhanji V, Sharma N, Vajpayee RB. Management of keratoconus: current scenario. *Br J Ophthalmol.* 2011; 95:1044-1050.
- Spoerl E, Huhle M, Seiler T. Induction of cross-links in corneal tissue. *Exp Eye Res.* 1998; 66:97-103.
- Spoerl E, Wollensak G, Seiler T. Increased resistance of crosslinked cornea against enzymatic digestion. *Curr Eye Res.* 2004; 29:35-40.
- Wollensak G, Spoerl E, Seiler T. Stress-strain measurements

- of human and porcine corneas after riboflavin–ultraviolet-A-induced cross-linking. *J Cataract Refract Surg.* 2003; 29:1780-1785.
6. Wittig-Silva C, Chan E, Islam FM, Wu T, Whiting M, Snibson GR. A randomized, controlled trial of corneal collagen cross-linking in progressive keratoconus: three-year results. *Ophthalmology.* 2014; 121:812-821.
 7. Hashemi H, Seyedian MA, Miraftab M, Fotouhi A, Asgari S. Corneal collagen cross-linking with riboflavin and ultraviolet A irradiation for keratoconus: long-term results. *Ophthalmology.* 2013; 120:1515-1520.
 8. Wang YM, Chan TC, Marco C, Jhanji V. Comparative evaluation of progression rate in keratoconus before and after collagen crosslinking. *Br J Ophthalmol.* 2018; 102:1109-1113.
 9. Asgari S, Hashemi H. OPD scan III accuracy: Topographic and aberrometric indices after accelerated corneal cross-linking. *J Curr Ophthalmol.* 2018; 30:58-62.
 10. Belin MW, Duncan J. Keratoconus: the ABCD grading system. *Klin Monbl Augenheilkd.* 2016; 233:701-707.
 11. Villavicencio OF, Gilani F, Henriquez MA, Izquierdo L, Ambrosio RR, Belin WM. Independent population validation of the Belin/Ambrosio enhanced ectasia display: Implications for keratoconus studies and screening. *Int J Kerat Ect Cor Dis.* 2014; 3: 1–8
 12. Ambrósio R, Caiado ALC, Guerra FP, Louzada R, Sinha RA, Luz A, et al. Novel pachymetric parameters based on corneal tomography for diagnosing keratoconus. *J Refract Surg.* 2011; 27:753-758.
 13. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-A-induced collagen crosslinking for the treatment of keratoconus. *Am J Ophthalmol.* 2003; 135:620-627.
 14. Mueller A, Thomas BC, Auffarth GU, Holzer MP. Comparison of a new image-guided system versus partial coherence interferometry, Scheimpflug imaging, and optical low-coherence reflectometry devices: keratometry and repeatability. *J Cataract Refract Surg.* 2016; 42: 672-678.
 15. Wang YM, Chan TC, Yu M, Jhanji V. Shift in progression rate of keratoconus before and after epithelium-off accelerated corneal collagen crosslinking. *J Cataract Refract Surg.* 2017; 43:929-936.
 16. Shajari M, Steinwender G, Herrmann K, Kubiak KB, Pavlovic I, Plawetzki E, et al. Evaluation of keratoconus progression. *Br J Ophthalmol.* 2018;bjophthalmol-2017-311651.
 17. Chow VW, Chan TC, Yu M, Wong VW, Jhanji V. One-year outcomes of conventional and accelerated collagen crosslinking in progressive keratoconus. *Sci Rep.* 2015; 5:14425.
 18. Uçakhan ÖÖ, Bayraktutar BN, Saglik A. Pediatric corneal collagen cross-linking: long-term follow-up of visual, refractive, and topographic outcomes. *Cornea.* 2016; 35:162-168.
 19. Mohammadpour M, Masoumi A, Mirghorbani M, Shahraki KI, Hashemi H. Updates on corneal collagen cross-linking: Indications, techniques and clinical outcomes. *J Curr Ophthalmol.* 2017.
 20. Kymionis GD, Tsoularas KI, Liakopoulos DA, Paraskevopoulos TA, Kouroumpi AI, Tsilimbaris MK. Excessive corneal flattening and thinning after corneal cross-linking: single-case report with 5-year follow-up. *Cornea.* 2015; 34:704-706.
 21. Kırgız A, Atalay K, Çabuk KŞ, Kaldırım H, Taşkapılı M. Factors affecting visual acuity after accelerated crosslinking in patients with progressive keratoconus. *Arq Bras Oftalmol.* 2016;79(3): 151-4.
 22. Steinberg J, Ahmadiyar M, Rost A, Frings A, Filev F, Katz T, Linke SJ. Anterior and posterior corneal changes after crosslinking for keratoconus. *Optom Vis Sci.* 2014;91(2): 178-86
 23. Henriquez MA, Izquierdo L Jr., Bernilla C, Zakrzewski PA, Maninis M. Riboflavin/ultraviolet A corneal collagen cross-linking for the treatment of keratoconus: visual outcomes and Scheimpflug analysis. *Cornea* 2011; 30:281-6
 24. Grewal DS, Brar GS, Jain R, Sood V, Singla M, Grewal SP. Corneal collagen crosslinking using riboflavin and ultraviolet-A light for keratoconus: one-year analysis using Scheimpflug imaging. *J Cataract Refract Surg* 2009; 35:425-32.